₹ 499.30
-1.20 (-0.24%)Open
500.55High
506.95Low
499.3Prev Close
500.5P/E
-Median P/E
31.48P/B
2.54Median P/B
4.77Market Cap
48.83BPEG
-Div.Yield
-Bid
499.30Ask
503.00Large Cap
48.83B Mkt. Cap.Volatility
-Beta
0.95Genie Says
Influencer Count
-Days | BSE | NSE |
---|
5 | 509.35 | 509.33 |
10 | 508.78 | 508.78 |
20 | 522.04 | 522.01 |
50 | 480.77 | 480.84 |
100 | 419.13 | 419.14 |
300 | 388.00 | 387.99 |
BSE
530549NSE
SHILPAMEDISIN
INE790G01031Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
Alpesh Dalal
Chief Financial OfficerRitu Tiwary
Compliance Officer, Company SecretaryVishnukant Bhutada
Managing Director, Executive DirectorSharath Kalakota
Whole-Time Director